Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 334-336

  Lee, Ah Hyun ^a   Lange, Claudia ^a   Ricken, Roland ^a   Hellweg, Rainer ^a   Lang, Undine E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

acute psychiatry; amisulpride; BDNF; brain derived neurotrophic factor; haloperidol; olanzapine; PANSS; quetiapine; risperidone; schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 79955593913     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31821895c1     Document Type: Article

References (28)

1. Lang UE, Puls I, Muller DJ, et al. Molecular mechanisms of schizophrenia. Cell Physiol Biochem. 2007;20:687-702. (Pubitemid 350059714)
2. Guillin O, Demily C, Thibaut F. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol. 2007;78:377-395.
3. Levine ES, Crozier RA, Black IB, et al. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad Sci USA. 1998;95:10235-10239. (Pubitemid 28415324)
4. Numakawa T, Takei N, Yamagishi S, et al. Neurotrophin-elicited short-term glutamate release from cultured cerebellar granule neurons. Brain Res. 1999;842:431-438. (Pubitemid 29475177)
5. Domenici E, Willé DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010;5:e9166.
6. Pillai A, Kale A, Joshi S, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol. 2009;13:535-539.
7. Lang UE, Hellweg R, Sander T, et al. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry. 2009;14:120-122.
8. Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID) I: history, rationale, and description. Arch Gen Psychiatry. 1992;49:624-629.
9. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-275.
10. Hellweg R, von Arnim CA, Büchner M, et al. Neuroprotection and neuronal dysfunction upon repetitive inhibition of oxidative phosphorylation. Exp Neurol. 2003;183:346-354. (Pubitemid 37205077)
11. Ziegenhorn AA, Schulte-Herbrüggen O, Danker-Hopfe H, et al. Serum neurotrophinsVa study on the time course and influencing factors in a large old age sample. Neurobiol Aging. 2007;28:1436-1445. (Pubitemid 47090171)
12. Hellweg R, Ziegenhorn A, Heuser I, et al. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry. 2008;41:66-71. (Pubitemid 351427525)
13. Buckley PF, Pillai A, Evans D, et al. Brain-derived neurotropic factor in first-episode psychosis. Schizophr Res. 2007;91:1-5.
14. Chen da C, Wang J, Wang B, et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naBve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl). 2009;207:375-380.
15. Jindal RD, Pillai AK, Mahadik SP, et al. Decreased BDNF in patients with antipsychotic naBve first episode schizophrenia. Schizophr Res. 2010;119:47-51.
16. Vinogradov S, Fisher M, Holland C, et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophreniä Biol Psychiatry. 2009;66:549-553.
17. Ikeda Y, Yahata N, Ito I, et al. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res. 2008;101:58-66.
18. Tan YL, Zhou DF, Cao LY, et al. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett. 2005;382:27-32.
19. Weickert CS, Hyde TM, Lipska BK, et al. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 2003;8:592-610. (Pubitemid 36898018)
20. Knable MB, Barci BM, Webster MJ, et al. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry. 2004;9:609-620. (Pubitemid 38850441)
21. Reis HJ, Nicolato R, Barbosa IG, et al. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett. 2008;439:157-159.
22. Rizos EN, Rontos I, Laskos E, et al. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1308-1311.
23. Rizos EN, Papadopoulou A, Laskos E, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 2010;11:251-255.
24. Yoshimura R, Hori H, Sugita A, et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1072-1077. (Pubitemid 46810098)
25. Czubak A, Nowakowska E, Kus K, et al. Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep. 2009;61:1017-1023.
26. Grillo RW, Ottoni GL, Leke R, et al. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res. 2007;41:31-35. (Pubitemid 44708213)
27. Lang UE. Impairment of phosphatidylinositol 3-kinase signaling in schizophrenia: state or trait? Am J Psychiatry. 2010;167:719.
28. Kalkman HO. The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol Ther. 2006;110: 117-134. (Pubitemid 43248729)